## Justine Defreyne

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5539871/publications.pdf

Version: 2024-02-01

35	788	16 h-index	27
papers	citations		g-index
35	35	35	595
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Change in Visceral Fat and Total Body Fat and the Effect on Cardiometabolic Risk Factors During Transgender Hormone Therapy. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e153-e164.	1.8	21
2	Characterisation of testicular function and spermatogenesis in transgender women. Human Reproduction, 2021, 36, 5-15.	0.4	17
3	Sexual orientation in transgender individuals: results from the longitudinal ENIGI study. International Journal of Impotence Research, 2021, 33, 694-702.	1.0	11
4	Positive and Negative Affect Changes during Gender-Affirming Hormonal Treatment: Results from the European Network for the Investigation of Gender Incongruence (ENIGI). Journal of Clinical Medicine, 2021, 10, 296.	1.0	12
5	Is there a need for liver enzyme monitoring in people using gender-affirming hormone therapy?. European Journal of Endocrinology, 2021, 184, 513-520.	1.9	15
6	Low feasibility of inÂvitro matured oocytes originating from cumulus complexes found during ovarian tissue preparation at the moment of gender confirmation surgery and during testosterone treatment for fertility preservation in transgender men. Fertility and Sterility, 2021, 116, 1068-1076.	0.5	27
7	Organizing the voice questionnaire for transgender persons. International Journal of Transgender Health, 2020, 21, 89-97.	1.1	10
8	Parental desire and fertility preservation in assigned male at birth transgender people living in Belgium. International Journal of Transgender Health, 2020, 21, 45-57.	1.1	13
9	Parental desire and fertility preservation in assigned female at birth transgender people living in Belgium. Fertility and Sterility, 2020, 113, 149-157.e2.	0.5	30
10	Effects of Gender-Affirming Hormone Therapy on Insulin Sensitivity and Incretin Responses in Transgender People. Diabetes Care, 2020, 43, 411-417.	4.3	41
11	Editorial: Transgender health care, what you missed during your training. International Journal of Impotence Research, 2020, 33, 669-670.	1.0	1
12	Vaginal bleeding and spotting in transgender men after initiation of testosterone therapy: A prospective cohort study (ENIGI). International Journal of Transgender Health, 2020, 21, 163-175.	1.1	36
13	OR27-05 Sexual Desire Changes in Transgender Individuals upon Initiation of Hormone Treatment; Results from the Longitudinal ENIGI Study. Journal of the Endocrine Society, 2020, 4, .	0.1	O
14	Lower Serum Estradiol Levels in Assigned Female at Birth Transgender People with Initiation of Testosterone Therapy: Results from the European Network for the Investigation of Gender Incongruence. LGBT Health, 2020, 7, 71-81.	1.8	9
15	Sexual Desire Changes in Transgender Individuals Upon Initiation of Hormone Treatment: Results From the Longitudinal European Network for the Investigation of Gender Incongruence. Journal of Sexual Medicine, 2020, 17, 812-825.	0.3	30
16	SAT-745 Lower Serum Estradiol Levels in Assigned Female at Birth Transgender People with Initiation of Testosterone Therapy: Results from the European Network for the Investigation of Gender Incongruence (ENIGI). Journal of the Endocrine Society, 2020, 4, .	0.1	0
17	Health considerations for transgender women and remaining unknowns: a narrative review. Therapeutic Advances in Endocrinology and Metabolism, 2019, 10, 204201881987116.	1.4	31
18	Transmasculine Hormone Therapy. Endocrinology and Metabolism Clinics of North America, 2019, 48, 357-375.	1.2	12

#	Article	IF	Citations
19	Sexual health, transition-related risk behavior and need for health care among transgender sex workers. International Journal of Transgenderism, 2019, 20, 388-402.	3.5	6
20	Cardiometabolic Effects of Testosterone in Transmen and Estrogen Plus Cyproterone Acetate in Transwomen. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 1937-1947.	1.8	63
21	No correlation between serum testosterone levels and state-level anger intensity in transgender people: Results from the European Network for the Investigation of Gender Incongruence. Hormones and Behavior, 2019, 110, 29-39.	1.0	25
22	Effects of Gender-Affirming Hormones on Lipid, Metabolic, and Cardiac Surrogate Blood Markers in Transgender Persons. Clinical Chemistry, 2019, 65, 119-134.	1.5	56
23	SAT-014 No Correlation between Serum Testosterone Levels and Aggression or Anger Intensity in Transgender People: Results from Five European Centres. Journal of the Endocrine Society, 2019, 3, .	0.1	0
24	Prospective evaluation of hematocrit in genderâ€affirming hormone treatment: results from European Network for the Investigation of Gender Incongruence. Andrology, 2018, 6, 446-454.	1.9	74
25	Routine histopathological examination after female-to-male gender-confirming mastectomy. British Journal of Surgery, 2018, 105, 885-892.	0.1	24
26	Effects of Sex Hormone Treatment on the Metabolic Syndrome in Transgender Individuals: Focus on Metabolic Cytokines. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 790-802.	1.8	49
27	Prospective Evaluation of Self-Reported Aggression in Transgender Persons. Journal of Sexual Medicine, 2018, 15, 768-776.	0.3	20
28	036 Trans persons' ideas and concerns about fertility and fertility preservation: a population-based survey. Journal of Sexual Medicine, 2018, 15, S139.	0.3	0
29	155 Is gender affirming hormonal therapy linked to aggression in transgender people?. Journal of Sexual Medicine, 2018, 15, S195.	0.3	0
30	Concerning the Article by Fung etÂal, Titled "Differential Effects of Cyproterone Acetate vs Spironolactone on Serum High-Density Lipoprotein and Prolactin Concentrations in the Hormonal Treatment of Transgender Women†Journal of Sexual Medicine, 2017, 14, 172-173.	0.3	0
31	Healthcare costs and quality of life outcomes following gender affirming surgery in trans men: a review. Expert Review of Pharmacoeconomics and Outcomes Research, 2017, 17, 543-556.	0.7	42
32	Transient Elevated Serum Prolactin in Trans Women Is Caused by Cyproterone Acetate Treatment. LGBT Health, 2017, 4, 328-336.	1.8	55
33	Selfâ€perception of voice in transgender persons during crossâ€sex hormone therapy. Laryngoscope, 2017, 127, 2796-2804.	1.1	44
34	P-01-002 Prospective analysis: Mild elevation in serum prolactin in trans women is caused by cyproterone acetate. Journal of Sexual Medicine, 2017, 14, e162.	0.3	0
35	Is Type 1 Diabetes Mellitus More Prevalent Than Expected in Transgender Persons? A Local Observation. Sexual Medicine, 2017, 5, e215-e218.	0.9	14